

CENTRAL PHARMACEUTICAL JOINT
STOCK COMPANY NO 2
NO: 120 / DPMV₂

(Under the Circular N.99/2025/TT_BTC dated
October 27, 2025 of the Minister of Finance)

FINANCIAL STATEMENTS

FIRST QUARTER 2026

Balance Sheet

Form: B01-DN

Income Statement

Form: B02-DN

Cash Flow Statement

Form: B03-DN

Notes to the financial statement

Form: B09-DN

Recipient:

Reporting entity: Central Pharmaceutical Joint Stock
Company NO2
Address: 9 Tran Thanh Tong Street, Hai Ba Trung Ward,
Hanoi

Form No. B 01 - DN
(Under the Circular No. 99/2025/TT-BTC dated October 27,
2025 of the Minister of Finance)

STATEMENT OF FINANCIAL POSITION

As of March 31, 2026

(Applicable to companies that are assumed to operate on a going concern basis)

Currency: VND

ASSET	Code	Note	Closing balance March 31, 2026	Opening balance December 31, 2025
1	2	3	4	5
A - CURRENT ASSETS	100		240.455.064.467	146.559.764.356
I. Cash and cash equivalents	110		108.263.088.171	21.401.284.733
1. Cash	111		108.263.088.171	21.401.284.733
2. Cash equivalents	112			
II. Current financial investments	120			
1. Trading securities	121			
2. Provision for impairment of trading securities (*)	122			
3. Held-to-maturity investments	123			
4. Provision for current investments held to maturity (*)	124			
5. Other current investments	125			
6. Provision for losses on other current investments (*)	126			
III. Current receivables	130		78.119.149.635	83.070.222.715
1. Trade receivables	131		21.098.165.576	24.452.737.412
2. Advances to suppliers	132		5.239.781.226	6.347.920.841
3. Intercompany receivables	133			
4. Receivables under construction contract progress	134			
5. Other current receivables	135		56.537.836.881	57.026.198.510
6. Provision for doubtful debts (*)	136		(4.756.634.048)	(4.756.634.048)
7. Shortage of assets awaiting resolution	137			
IV. Inventories	140		53.090.904.776	41.638.709.523
1. Inventories	141		53.090.904.776	41.638.709.523
2. Provision for impairment of inventories (*)	142			
V. Current biological assets	150			
1. Livestock for a single harvest	151			
2. Seasonal or single harvest crops	152			
3. Provision for current biological asset losses (*)	153			
VI. Other current assets	160		981.921.885	449.547.385
1. Prepaid expenses	161		413.619.949	321.889.116
2. Deductible VAT	162		459.289.886	58.648.144
3. Taxes and other receivables from the State	163		109.012.050	69.010.125
4. Government bond repurchase transactions	164			
5. Other current assets	165			

B - NON-CURRENT ASSETS	200		164.689.388.175	263.882.042.788
I. Non-current receivables	210		45.000.000.000	45.000.000.000
1. Trade receivables	211			
2. Advances to suppliers	212			
3. Business capital in subsidiaries	213			
4. Non-current intercompany receivables	214			
5. Other non-current receivables	215		45.000.000.000	45.000.000.000
6. Provision for doubtful receivables (*)	216			
II. Fixed assets	220		105.845.664.155	110.731.893.402
1. Tangible fixed assets	221		105.845.664.155	110.731.893.402
- Original cost	222		290.969.213.635	290.298.359.931
- Accumulated depreciation (*)	223		(185.123.549.480)	(179.566.466.529)
2. Fixed assets under finance lease	224			
- Original cost	225			
- Accumulated depreciation (*)	226			
3. Intangible fixed assets	227			
- Original cost	228		810.751.750	810.751.750
- Accumulated depreciation (*)	229		(810.751.750)	(810.751.750)
III. Non-current biological assets	230			
1. Livestock for periodic output	231			
a) Livestock not reaching maturity for periodic output	232			
b) Livestock reaching maturity for periodic output	233			
- Original cost	234			
- Accumulated depreciation (*)	235			
1. Livestock for a single harvest	236			
2. Seasonal or single harvest crops	237			
3. Provision for biological asset losses (*)	238			
IV. Investment properties	240			
- Original cost	241			
- Accumulated depreciation (*)	242			
V. Non-current assets in progress	250		76.805.661	76.805.661
1. Work in progress	251			
2. Construction in progress	252		76.805.661	76.805.661
VI. Non-current financial investments	260			93.960.000.000
1. Investments in subsidiaries	261			
2. Investments in associates and joint-ventures	262			
3. Investments in other entities	263			93.960.000.000
4. Provision for financial investments in other entities (*)	264			
4. Provision for financial investments (*)	265			

5. Held-to-maturity investments	266			
VII. Other non-current assets	270		13,766,918.359	14,113,343.725
1. Non-current prepaid expenses	271		13,766,918.359	14,113,343.725
2. Deferred income tax assets	272			
3. Non-current equipment, supplies and spare parts for replacement	273			
4. Other non-current assets	274			
TOTAL ASSETS (280 = 100 + 200)	280		405,144,452.642	410,441,807.144
C - LIABILITIES	300		341,869,995.658	340,281,443.613
I. Current liabilities	310		247,909,995.658	246,321,443.613
1. Trade payables	311		18,254,245.729	17,455,520.732
2. Advances from customers	312		27,839,427.593	25,699,505.157
3. Dividend and profit payables	313			
4. Taxes and payables to the State budget	314		53,621,706.734	54,059,183.722
5. Payables to employees	315		1,783,671.570	3,559,635.569
6. Accrued expenses	316		49,471,029.694	46,692,554.187
7. Inter-company payables	317			
8. Payables under the progress of construction contracts	318			
9. Current deferred revenue	319			
10. Other current payables	320		1,539,282.252	1,354,412.160
11. Current borrowings and finance lease liabilities	321		95,115,578.312	97,215,578.312
12. Provision for payables	322			
13. Welfare and reward fund	323		285,053.774	285,053.774
14. Pricing stabilization fund	324			
15. Government bonds purchased for resale	325			
II. Non-current liabilities	330		93,960,000.000	93,960,000.000
1. Trade payables	331			
2. Advances from customers	332			
3. Taxes and payables to the State budget	333			
4. Accrued expenses	334			
5. Inter-company capital payables	335			
6. Inter-company payables	336			
7. Deferred revenue	337			
8. Other payables	338		93,960,000.000	93,960,000.000
9. Borrowings and finance lease liabilities	339			
10. Convertible bonds	340			
11. Preferred shares	341			
12. Deferred income tax liabilities	342			
13. Provision for payables	343			
14. Technological and scientific development fund	344			
D - EQUITY	400		63,274,456.984	70,160,363.531
1. Owner's capital	411		200,000,000.000	200,000,000.000
- Ordinary shares with voting rights	411a		200,000,000.000	200,000,000.000
- Preference shares	411b			
2. Capital surplus	412		4,902,500.000	4,902,500.000
3. Option for conversion of bonds	413			

4. Other capital	414			
5. Acquisition of own shares (*)	415			(...)
6. Differences on revaluation of assets	416			
7. Foreign exchange differences	417			
8. Development and investment fund	418		3.267.017.189	3.267.017.189
9. Quỹ khác thuộc vốn chủ sở hữu	419		425.238.734	425.238.734
10. Retained earnings	420		(145.320.298.939)	(138.434.392.392)
- Retained earnings brought forward	420a		(138.434.392.392)	(127.621.896.962)
- Retained earnings for the current year	420b		(6.885.906.547)	(10.812.495.430)
TOTAL RESOURCES (440 = 300 + 400)	440		405.144.452.642	410.441.807.144

Approved on date 15 month 4 year... 2026

PREPARER
(Signature, full name)



Dinh Thị Minh Hương

CHIEF ACCOUNTANT
(Signature, full name)



CN. Nguyễn Thị Diệu Thúy

LEGAL REPRESENTATIVE
(Signature, full name and seal)



TỔNG GIÁM ĐỐC
DS. Lê Tiến Dũng

Reporting entity: Central Pharmaceutical Joint
Stock Company NO2
Address: 9 Tran Thanh Tong Street, Hai Ba
Trung Ward, Hanoi

Form No. B 02 - DN
(Under the Circular No. 99/2025/TT-BTC dated
October 27, 2025 of the Minister of Finance)

INCOME STATEMENT

Accounting period from January 1, 2026 to March 31, 2026

Currency: VND

ITEM	Code	Note	Current quarter	Same quarter previous year	Cumulative figure from the beginning of current year to the end of current quarter	Cumulative figure from the beginning of the previous year to the end of the same quarter
1	2	3	4	5	6	7
1. Revenue from sale of goods and supply of services	01		29.351.445.432	41.509.407.053	29.351.445.432	41.509.407.053
2. Revenue deductions	02				-	-
3. Net revenue from sale of goods and supply of services (10 = 01 - 02)	10		29.351.445.432	41.509.407.053	29.351.445.432	41.509.407.053
4. Costs of goods sold	11		29.194.690.884	38.584.533.087	29.194.690.884	38.584.533.087
5. Gross profit from sale of goods and supply of services (20 = 10 - 11)	20		156.754.548	2.924.873.966	156.754.548	2.924.873.966
6. Profit/loss from the sale and disposal of investment properties.	21				-	-
7. Financial income	22		14.483.641	4.937.658	14.483.641	4.937.658
8. Financial expenses	23		2.824.924.507	2.788.326.272	2.824.924.507	2.788.326.272
- Including: Interest expense	24		2.813.674.007	2.778.025.172	2.813.674.007	2.778.025.172
8. Selling expenses	25		923.572.161	779.466.057	923.572.161	779.466.057
9. General and administrative expenses	26		3.226.498.527	2.839.647.444	3.226.498.527	2.839.647.444
11. Net profit from operating activities {30 = 20+21 + 22 - (23 + 25 + 26)}	30		(6.803.757.006)	(3.477.628.149)	(6.803.757.006)	(3.477.628.149)
12. Other income	31			53.352.991	-	53.352.991
13. Other expenses	32		82.149.541	28.582.153	82.149.541	28.582.153
14. Other profit (40 = 31 - 32)	40		(82.149.541)	24.770.838	(82.149.541)	24.770.838
15. Total profit before tax (50 = 30 + 40)	50		(6.885.906.547)	(3.452.857.311)	(6.885.906.547)	(3.452.857.311)
16. Current corporate income tax	51				-	-
17. Deferred corporate income tax	52				-	-
18. Profit after corporate income tax (60 = 50- 51 - 52)	60		(6.885.906.547)	(3.452.857.311)	(6.885.906.547)	(3.452.857.311)
19. Basic earnings per share (*)	70				-	-
20. Diluted earnings per share (*)	71				-	-

PREPARER

(Signature, full name)

Dinh Thi Minh Huong

CHIEF ACCOUNTANT

(Signature, full name)

CN. Nguyen Thi Dieu Thuy

Approved on date 15 month 4 year 2026

LEGAL REPRESENTATIVE

(Signature, full name and seal)



TỔNG GIÁM ĐỐC

DS. Lê Tiến Dũng

Reporting entity: Central Pharmaceutical Joint Stock Company
NO2
Address: 9 Tran Thanh Tong Street, Hai Ba Trung Ward, Hanoi

Form No B 03 - DN
(Under the Circular No. 99/2025/TT-BTC dated
October 27, 2025 of the Minister of Finance)

CASH FLOW STATEMENT
(Direct method) ()*

Accounting period from January 1, 2026 to March 31, 2026

Currency: VND

Item	Code	Note	Current year	Previous year
1	2	3	4	5
I. Cash flows from operating activities				
1. Proceeds from sale of goods and supply of services and	01		36.000.242.129	34.499.985.984
2. Payments to suppliers of goods and services	02		(31.983.758.720)	(26.983.911.511)
3. Payments to employees	03		(6.838.294.250)	(6.707.150.175)
4. Interest paid	04		(94.570.000)	(849.320.000)
5. Corporate income tax paid	05			
6. Other proceeds from operating activities	06		465.654.318.172	3.567.184.146
7. Other payments for operating activities	07		(467.736.133.893)	(5.999.856.578)
Net cash flows from operating activities	20		(4.998.196.562)	(2.473.068.134)
II. Cash flows from investing activities				
1. Purchase and construction of fixed assets and other non-current assets	21			
2. Proceeds from disposal and liquidation of fixed assets, and other non-current assets	22		93.960.000.000	
3. Loans to and purchase of debt instruments from other entities	23			
4. Recovery of loans and disposal of debt instruments of the other entities	24			
5. Investments in other entities	25			
6. Withdrawal of investments in other entities	26			
7. Proceeds from loan interest, dividends and profit shared	27			
Net cash flows from investing activities	30		93.960.000.000	
III. Cash flows from financing activities				
1. Proceeds from issuance of shares and capital contributions from shareholders	31			
2. Repayments of capital contributions to shareholders and redemption of issued shares	32			
3. Proceeds from borrowings	33			200.000.000
4. Repayments of principal	34		(2.100.000.000)	
5. Payments of lease liabilities	35			
6. Dividends and profit paid to shareholders	36			
Net cash flows from financing activities	40		(2.100.000.000)	200.000.000
Net cash flows for period (50 = 20+30+40)	50		86.861.803.438	(2.273.068.134)
Cash and cash equivalents at the beginning of the period	60		21.401.284.733	5.053.168.373

Effects of fluctuations in foreign exchange rates	61			
Cash and cash equivalents at the end of the period (70 = 50+60+61)	70		108.263.088.171	2.780.100.239

Approved on date 15 month 4 year 2026

PREPARER

(Signature, full name)



Đinh Thị Minh Hương

CHIEF ACCOUNTANT

(Signature, full name)



CN. Nguyễn Thị Diệu Thúy

LEGAL REPRESENTATIVE

(Signature, full name and seal)



TỔNG GIÁM ĐỐC

DS. Lê Tiến Dũng

NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

I. Additional information for items presented in the Balance Sheet

1. Cash

	31/03/2026	01/01/2026
	VND	VND
Cash on hand	52.275.344	336.513.349
Cash in bank	108.210.812.827	21.064.771.384
Total	108.263.088.171	21.401.284.733

2. Financial investments

Investments in other entities

	31/03/2026		01/01/2026	
	VND		VND	
	Historical cost	Provision	Historical cost	Provision
<i>Long-term</i>				
Binh An Developed Investment Joint Stock Company (i)	-	-	93.960.000.000	-
Total	-	-	93.960.000.000	-

3. Trade receivables

	31/03/2026		01/01/2026	
	VND		VND	
	Amount	Provision	Amount	Provision
<i>Short-term</i>				
Vinh Quang Independent	765.776.634	-	765.776.634	-
Tam Phat Pharmaceutical	4.018.928.853	-	3.818.870.208	-
Huong Viet Pharmaceutical JSC	1.358.617.919	-	1.626.060.007	-
Sapphire Pharmaceutical	893.686.906	-	1.048.414.352	-
Hoang Van Vi	2.845.103.060	-	3.180.368.960	-
Others	11.216.052.204	-	14.013.247.251	-
Total	21.098.165.576	-	24.452.737.412	-

4. Advances to suppliers

	31/03/2026	01/01/2026
	VND	VND
BMN Medical and Scientific Instrument Comp	1.828.344.000	2.064.461.000
Indochina International Joint Stock Company	879.984.000	549.990.000
MEDIPLANTEX ,JSC	-	2.629.491.197
Others	2.531.453.226	1.103.978.644

NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

Total			5.239.781.226	6.347.920.841
5. Other receivables				
	31/03/2026		01/01/2026	
	VND		VND	
	Amount	Provision	Amount	Provision
<i>a) Short-term</i>	<i>56.537.836.881</i>		<i>57.026.198.510</i>	
Advances	113.627.426		133.627.426	
<i>Vu Thi Thu Hang</i>	<i>41.302.000</i>		<i>41.302.000</i>	
<i>Others</i>	<i>72.325.426</i>		<i>92.325.426</i>	
Mortgages, collaterals	534.848.680		468.895.076	
Social insurance paid for	653.726.245		1.081.477.763	
Other receivables	55.235.634.530		55.342.198.245	
<i>Binh An Developed Investment JSC (i)</i>	<i>49.503.225.723</i>		<i>49.600.314.938</i>	
<i>Tran Bao Cuong</i>	<i>2.320.000.000</i>		<i>2.320.000.000</i>	
<i>Others</i>	<i>3.412.408.807</i>		<i>3.421.883.307</i>	
<i>b) Long-term</i>	<i>45.000.000.000</i>	-	<i>45.000.000.000</i>	-
Other receivables	45.000.000.000	-	45.000.000.000	-
<i>Nhat Minh Production Company Limited (ii)</i>		-	-	-
Nhat Minh Production Company Limited Branch in Hanoi (i)	45.000.000.000		45.000.000.000	
Total	101.537.836.881	-	102.026.198.510	-

6 Inventories

	31/03/2026		01/01/2026	
	VND		VND	
	Cost	Provision	Cost	Provision
Raw material	33.091.092.896	-	29.311.927.146	-
Tools and supplies	40.555.541	-	62.419.342	-
Work in progress	6.131.094.105	-	1.769.200.351	-
Finished goods	13.828.162.234	-	10.495.162.684	-
Total	53.090.904.776	-	41.638.709.523	-

NOTES TO THE FINANCIAL STATEMENTS*(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)***7. Construction in progress**

	31/03/2026 VND	01/01/2026 VND
Cao Xoa production line project	-	-
Vinh Tuy complex building	76.805.661	76.805.661
Total	76.805.661	76.805.661

8. Trade payables

	31/03/2026 VND		01/01/2026 VND	
	Historical cost	Amount payable	Historical cost	Amount payable
<i>Short-term</i>				
VCP.,JSC	-	-	-	-
Van Son International Economic and Technical Cooperation	7.346.050.277	7.346.050.277	7.346.050.277	7.346.050.277
MI Pharma Private Limited	1.630.205.570	1.630.205.570	1.630.205.570	1.630.205.570
Aristopharma LTD	-	-	-	-
Others	9.277.989.882	9.277.989.882	8.479.264.885	8.479.264.885
Total	18.254.245.729	18.254.245.729	17.455.520.732	17.455.520.732

9. Advances from customers

	31/03/2026 VND	01/01/2026 VND
<i>Short-term</i>		
Generic Pharmaceutical JSC	-	-
South East Of Asia Pharma.,JSC	2.002.302.633	4.111.326.121
Southeast Asia Pharmaceutical and Medical Equipment JSC	-	-
Xuan Anh Pharmaceutical and Equipment Company Limited	15.043.943.401	12.634.678.283
Capital Pharmacy.,JSC	847.510.360	-
HA MINH TECHNO CO., LTD	97.807.493	263.644.206
HUNG VIET TRADING AND PHARMACEUTICAL JOINT STOCK COM	988.588.477	988.588.477
Others	8.859.275.229	7.701.268.070
Total	27.839.427.593	25.699.505.157

10. Other payables

NOTES TO THE FINANCIAL STATEMENTS*(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)*

	31/03/2026	01/01/2026
	VND	VND
a) Short-term	1.539.282.252	1.354.412.160
Trade Union Fee	515.266.242	828.723.051
Other payables	1.024.016.010	525.689.109
Nhat Minh Production Company Limited Branch in Hanoi (i)	-	-
Others	1.024.016.010	525.689.109
b) Long-term	93.960.000.000	93.960.000.000
Other payables	93.960.000.000	93.960.000.000
Binh An Developed Investment Joint Stock Company (ii)	93.960.000.000	93.960.000.000
Total	95.499.282.252	95.314.412.160

11. Owner's equity*Details of owner's equity contribution*

	31/03/2026	01/01/2026
	VND	VND
Vietnam Pharmaceutical Corporation - JSC	13.566.500.000	13.566.500.000
Viet Land Corporation	24.748.000.000	24.748.000.000
Saigon Handicraft Fine Art Export Joint Stock Company	150.000.000.000	150.000.000.000
Other shareholders	11.685.500.000	11.685.500.000
Total	200.000.000.000	200.000.000.000

II. Additional information for items presented in the Income Statement**1. Gross revenue from goods sold and services rendered**

	Q1/2026	Q1/2025
	VND	VND
Revenue		
Revenue from sales of goods	-	-
Revenue from sales of finished products	29.351.445.432	41.509.407.053
Total	29.351.445.432	41.509.407.053

2. Revenue deductions

	Q1/2026	Q1/2025
	VND	VND
Sales Returns	-	-
Total	-	198.498.472

NOTES TO THE FINANCIAL STATEMENTS*(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)***3. Cost of sales**

	Q1/2026 VND	Q1/2025 VND
Cost of goods sold	-	-
Cost of finished goods sold	29.194.690.884	38.584.533.087
Total	29.194.690.884	38.584.533.087

4. Financial income

	Q1/2026 VND	Q1/2025 VND
Interest on bank deposits and margin interest	7.372.438	1.944.758
Exchange rate difference interest arises during the year	7.111.203	2.992.900
Gain from exchange rate difference due to revaluation at the year end	-	-
Total	14.483.641	4.937.658

5. Financial expenses

	Q1/2026 VND	Q1/2025 VND
Interest expense	2.813.674.007	2.778.025.172
Interest on late payment	-	-
Exchange rate difference loss arising during the year	12.896.000	10.301.100
Loss from exchange rate difference due to revaluation at the year end	-	-
Total	2.826.570.007	2.788.326.272

6. Other income

	Q1/2026 VND	Q1/2025 VND
Income from warehouse leasing	-	13.352.180
Income from liabilities that are not payable	-	-
Other	-	40.000.811
Total	-	53.352.991

7. Other expenses

	Q1/2026 VND	Q1/2025 VND
Administrative fines and late payment of taxes and insurance	80.452.792	-

NOTES TO THE FINANCIAL STATEMENTS*(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)*

Liquidation of defective raw materials and finished goods	-	-
Excess materials used for waste disposal	-	-
Other	1.696.749	28.582.153
Total	82.149.541	28.582.153

Approved on date 15 month 4 year 2026

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

Legal Representative



Dinh Thi Minh Huong



Nguyen Thi Dieu Thuy



Le Tien Dung

CENTRAL PHARMACEUTICAL
JOINT STOCK COMPANY NO2SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 122/CBTT-DPTU2

Hanoi, April 15, 2026

PERIODIC DISCLOSURE OF FINANCIAL STATEMENTS

To: Hanoi Stock Exchange

4nd quarter 2025 with Hanoi Stock Exchange as follows:

Pursuant to the provisions of Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding disclosures on the stock market, Central Pharmaceutical Joint Stock Company No2 shall disclose information on the financial statements (FS) 1nd quarter 2026 with Hanoi Stock Exchange as follows:

1. Company name:

- Ticker symbol: DP2
- Address: No. 9 Tran Thanh Tong Street, Ward Hai Ba Trung District, Hanoi.
- Tel: 024 39716579/91: Fax: 024 35251484.
- Email: dopharma@dopharma.com.vn.
- Website: wwwdophrma.com.vn _ dopharma.vn

2. Disclosures:

- Financial statements for the 1st quarter of 2026

☒ Separate financial statements (The listed company has no subsidiaries and the superior accounting entity has affiliates);

☐ Consolidated financial statements (the listed company has subsidiaries);

☐ Combined financial statements (the listed company has affiliated accounting entities with separate accounting apparatus).

- Cases that require explanation:

+ The auditors gave an opinion that was not an unqualified opinion on the financial statements (for audited financial statements in 2025):

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ The difference between pre- and post-audit profit in the reporting period is 5% or more, transferring from loss to profit or vice versa (for audited financial statements in 2024):



☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

+ Profit after corporate income tax in the income statement of the reporting period changes by 10% or more compared to the same reporting period of the previous year:

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ Profit after tax in the reporting period is a loss, transferring from profit in the same period of the previous year to loss in this period or vice versa:

☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

This information was announced on the company's website on April 20, 2026 at the link: www.dopharma.com.vn_dopharma.vn



For the Company

Legal representative/ person authorized to make disclosures

(Signature, full name, position, seal)

Attachments:

- Financial report for the first quarter of 2026
- Document explaining the financial statements for the first quarter of 2026



Pharmacist Le Tien Dung